Optic neuritis associated with adalimumab in the treatment of uveitis

Ocular Immunology and Inflammation

Volumn 18, Issue 6, 2010, Pages 475-481

  Li, Sing Your ^a   Birnbaum, Andrea D ^a   Goldstein, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

adalimumab; demyelination; multiple sclerosis; optic neuritis; TNF inhibition; uveitis

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; ETANERCEPT; INFLIXIMAB; LENERCEPT; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BLOOD DYSCRASIA; CASE REPORT; CHOROIDITIS; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE PREDISPOSITION; DRUG INDUCED CANCER; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; INFECTION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LYMPHOMA; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PSORIATIC ARTHRITIS; RETINA MACULA CYSTOID EDEMA; RETROBULBAR DEMYELINATING OPTIC NEURITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS INFECTION; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BRAIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; IRIDOCYCLITIS; MAGNETIC RESONANCE IMAGING; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VISUAL FIELDS;

EID: 78649246125     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2010.495814     Document Type: Article

References (43)

1. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of effcacy and safety. Clin Immunol. 2008: 126(1):13-30.
2. Theodossiadis PG, Markomichelakis NN, Sfkakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular infammation. Retina. 2007: 27(4):399-413.
3. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infiximab, a chime-ric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003: 107(25):3133-3140.
4. De Bandt M, Sibilia J, Le Loët X, et al. Systemic lupus ery-thematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005: 7(3):R545-R551.
5. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004: 31(10):1955-1958.
6. Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelina-tion during anti-tumor necrosis factor alpha therapy with infiximab for Crohn's disease. Infamm Bowel Dis. 2004: 10(1):28-31.
7. Bellesi M, Logullo F, Di Bella P, et al. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol. 2006: 253(5):668-669.
8. Tanno M, Nakamura I, Kobayashi S, et al. New-onset demy-elination induced by infiximab therapy in two rheumatoid arthritis patients. Clin Rheumatol. 2006: 25(6):929-933.
9. Vadikolias K, Kouklakis G, Heliopoulos I, et al. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease. Eur J Gastroenterol Hepatol. 2007: 19(2):159-162.
10. Fromont A, De Seze J, Fleury MC, et al. Infammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009: 45(2):55-57.
11. Dubcenco E, Ottaway CA, Chen DL, et al. Neurological symptoms suggestive of demyelination in Crohn's disease after infiximab therapy. Eur J Gastroenterol Hepatol. 2006: 18(5):565-566.
12. Jarand J, Zochodne DW, Martin LO, et al. Neurological complications of infiximab. J Rheumatol. 2006: 33(5):1018-1020.
13. Hamon MA, Nicolas G, Deviere F, et al. [Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature.] Rev Neurol. 2007: 163(12):1232-1235. Article in French.
14. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009: 66(4):490-497.
15. Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006: 54(5):1429-1434.
16. Von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. Ophthalmologica. 2008: 222(4): 292-294.
17. Bensouda-Grimaldi L, Mulleman D, Valat JP, et al. Adal-imumab-associated multiple sclerosis. J Rheumatol. 2007: 34(1):239-240.
18. Chung JH, Van Stavern GP, Frohman LP, et al. Adalimum-ab-associated optic neuritis. J Neurol Sci. 2006: 244(1-2): 133-136.
19. Foroozan R, Buono LM, Sergott RC, et al. Retrobulbar optic neuritis associated with infiximab. Arch Ophthalmol. 2002: 120(7):985-987.
20. Strong BY, Erny BC, Herzenberg H, et al. Retrobulbar optic neuritis associated with infiximab in a patient with Crohn disease. Ann Intern Med. 2004: 140(8):W34.
21. Tran TH, Milea D, Cassoux N, et al. [Optic neuritis associated with infiximab.] J Fr Ophtalmol. 2005: 28(2):201-204. Article in French.
22. Ten Tusscher M P, Jacobs PJ, Busch MJ, et al. Bilateral anterior toxic optic neuropathy and the use of infiximab. BMJ. 2003: 326(7389):579.
23. Mejico LJ. Infiximab-associated retrobulbar optic neuritis. Arch Ophthalmol. 2004: 122(5):793-794.
24. Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2007: 66(9):1255-1258.
25. Mumoli N, Niccoli G, Scazzeri F, et al. Infiximab-induced retrobulbar optic neuritis. QJM. 2007: 100(8):531.
26. Bidaguren A, Müller-Thyssen A, Blanco A, et al. [Retrobul-bar optic neuritis associated with Infiximab.] Arch Soc Esp Oftalmol. 2007: 82(2):109-112. Article in Spanish.
27. Hejazi R, Colombel JF, Peyrin-Biroulet L. [Retrobulbar optic neuritis during infiximab treatment for ulcerative colitis.] Gastroenterol Clin Biol. 2008: 32(2):162-163. Article in French.
28. Zannin ME, Martini G, Buscain I, et al. Sudden visual loss in a child with juvenile idiopathic arthritis-related uveitis. Br J Ophthalmol. 2009: 93(3):282-283, 417.
29. Tauber T, Turetz J, Barash J, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. J AAPOS. 2006: 10(1):26-29.
30. Noguera-Pons R, Borrás-Blasco J, Romero-Crespo I, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. 2005: 39(12):2131-2135.
31. Magnano MD, Robinson WH, Genovese MC. Demyelina-tion and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004: 22(5 Suppl 35):S134-S140.
32. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for infammatory arthritides. Arthritis Rheum. 2001: 44(12):2862-2869
33. Food and Drug Administration Center for Drug Evaluation and Research. March 4, 2003 meeting of the Arthritis Advisory Committee. Safety update meeting on TNF blocking agents. Available from: www.fda.gov/ohrms/dockets/ac/03/ briefng/3930B1-01-B-TNF.Briefng.pdf. Accessed March 28, 2010
34. Optic Neuritis Study Group. The clinical profle of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991: 109(12):1673-1678.
35. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001: 50(1):121-127.
36. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med. 1991: 325 (7):467-472.
37. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996: 47(6):1531-1534
38. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 1999: 53(3):457-465.
39. Gupta G, Gelfand JM, Lewis JD. Increased risk for demy-elinating diseases in patients with infammatory bowel disease. Gastroenterology. 2005: 129(3):819-826.
40. Prahalad S, Shear ES, Thompson SD, et al. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis. Arthritis Rheum. 2002: 46(7):1851-1856.
41. Lin P, Tessler HH, Goldstein DA. Family history of infam-matory bowel disease in patients with idiopathic ocular infammation. Am J Ophthalmol. 2006: 141(6):1097-1104.
42. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol. 2003: 250(6):672-675.
43. Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology. 1999: 53(4):883-885.